DURHAM, N.C., April 4, 2024 /PRNewswire/ -- The Rare Cancer Research Foundation (RCRF) is proud to announce an exciting collaboration with Spanios aimed at propelling the discovery and validation of groundbreaking therapeutic options for rare cancers.

Spanios, a firm that created and leverages its unique 3D tumoroid platforms to validate solid tumor therapies today announced a partnership with Accelerated Biosciences, a company that licenses its commercial-grade human trophoblast stem cell (hTSC) platform for drug discovery, therapeutic development, biomanufacturing, and toxicology testing.

Spanios is pleased to confirm the execution of a co-marketing agreement (the “Agreement”) with Inaphaea a UK based high throughput drug screening services using its Patient Derived Cells (“PDC”) as a precursor to Spanos’s proprietary Patient Derived Tumoroids (“PDT”).